Jim Dickinson recently published an article on the Medical Device and Diagnostic Industry website about the most recent Health and Human Services Office of the Inspector General (OIG) report.  The report raises the issue of whether or not FDA should be forced to tighten their review process for Sponsor’s to submit complete financial disclosure information on investigators with IND/IDE applications.  The article also mentions that OIG is critical of FDA’s current adverse event reporting review process.  With that being said, OIG will be re-focusing a previous recommendation that FDA obtain complete financial disclosure information, as well as develop more strict device adverse event reporting review requirements.